Cargando…

Low Dose Rivaroxaban for Atherosclerotic Cardiovascular Diseases: A Systematic Review and Meta-analysis

Background: This study aims to explore the role of low-dose rivaroxaban (≤10 mg daily) for the treatment of atherosclerotic cardiovascular disease (ASCVD). Methods: PubMed, Embase and the Cochrane Library were searched for randomized controlled trials (RCTs) of low-dose rivaroxaban in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Can, Kan, Yuanqing, Shi, Zhenyu, Guo, Daqiao, Fu, Weiguo, Li, Yanli, Lv, Qianzhou, Li, Xiaoyu, Si, Yi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957832/ https://www.ncbi.nlm.nih.gov/pubmed/33732144 http://dx.doi.org/10.3389/fphar.2020.608247

Ejemplares similares

The Impact of Dabigatran and Rivaroxaban on Variation of Platelet Activation Biomarkers and DRT Following Percutaneous Left Atrial Appendage Closure
por: Li, Xiaoye, et al.
Publicado: (2021)

Evaluation of Remote Pharmacist-Led Outpatient Service for Geriatric Patients on Rivaroxaban for Nonvalvular Atrial Fibrillation During the COVID-19 Pandemic
por: Li, Xiaoye, et al.
Publicado: (2020)

Do fluoroquinolones increase aortic aneurysm or dissection incidence and mortality? A systematic review and meta-analysis
por: Chen, Can, et al.
Publicado: (2022)

Clinical Efficacy and Safety Comparison of Rivaroxaban and Dabigatran for Nonvalvular Atrial Fibrillation Patients Undergoing Percutaneous Left Atrial Appendage Closure Operation
por: Li, Xiaoye, et al.
Publicado: (2021)

Benefits and Harms of Low-Dose Rivaroxaban in Asian Patients With Atrial Fibrillation: A Systematic Review and Meta-analysis of Real-World Studies
por: Qian, Jun, et al.
Publicado: (2021)

Vancomycin Associated Acute Kidney Injury: A Longitudinal Study in China
por: Kunming, Pan, et al.
Publicado: (2021)

Low-dose rivaroxaban: can cardiovascular events be reduced?
por: De Luca, Leonardo
Publicado: (2023)

Cost-Effectiveness Analysis of Rivaroxaban in Chinese Patients With Stable Cardiovascular Disease
por: Feng, Tianyu, et al.
Publicado: (2022)

Homocysteine Impairs Endothelial Cell Barrier Function and Angiogenic Potential via the Progranulin/EphA2 Pathway
por: Tian, Dan, et al.
Publicado: (2021)

Evaluation for the safety and effectiveness of the in situ fenestration system in TEVAR for aortic arch pathologies: protocol for a prospective, multicentre and single-arm study
por: Sun, Xiaofan, et al.
Publicado: (2021)

Meta-analysis and trial sequential analysis of ezetimibe for coronary atherosclerotic plaque compositions
por: Chai, Bofeng, et al.
Publicado: (2023)

Platelet Function and Risk of Bleeding in Patients With Acute Coronary Syndrome Following Tirofiban Infusion
por: Li, Xiaoye, et al.
Publicado: (2019)

In vivo evaluation of the pharmacokinetic interactions between almonertinib and rivaroxaban, almonertinib and apixaban
por: Wang, Zhi, et al.
Publicado: (2023)

Rivaroxaban in heart failure patients with left ventricular thrombus: A retrospective study
por: Zhang, Qian, et al.
Publicado: (2022)

Real-World Data of Tigecycline-Associated Drug-Induced Liver Injury Among Patients in China: A 3-year Retrospective Study as Assessed by the Updated RUCAM
por: Shi, Xiaoping, et al.
Publicado: (2021)

Single and Repeated Doses of EGb 761(®) do not Affect Pharmacokinetics or Pharmacodynamics of Rivaroxaban in Healthy Subjects
por: Hoerr, Robert, et al.
Publicado: (2022)

A Combined Pharmacometrics Analysis of Biomarker Distribution Under Treatment With Standard- or Low-Dose Rivaroxaban in Real-World Chinese Patients With Nonvalvular Atrial Fibrillation
por: Zhao, Nan, et al.
Publicado: (2022)

Vancomycin associated acute kidney injury in patients with infectious endocarditis: a large retrospective cohort study
por: Kunming, Pan, et al.
Publicado: (2023)

The discovery of rivaroxaban: translating preclinical assessments into clinical practice
por: Kubitza, Dagmar, et al.
Publicado: (2013)

Atorvastatin Therapy Modulates Telomerase Activity in Patients Free of Atherosclerotic Cardiovascular Diseases
por: Strazhesko, Irina D., et al.
Publicado: (2016)

Long-term outcomes following exclusive use of endovascular aortic repair for ruptured infrarenal abdominal aortic aneurysms
por: Wang, Ruihan, et al.
Publicado: (2023)

Sequential Therapy of Nadroparin and Rivaroxaban in the Initial Treatment of Patients With Acute Pulmonary Embolism
por: Xiong, Wei, et al.
Publicado: (2022)

Rivaroxaban-Induced Hemorrhage Associated with ABCB1 Genetic Defect
por: Ing Lorenzini, Kuntheavy, et al.
Publicado: (2016)

Trained immunity in monocyte/macrophage: Novel mechanism of phytochemicals in the treatment of atherosclerotic cardiovascular disease
por: Wang, Jie, et al.
Publicado: (2023)

Successful treatment discontinuation in CML patients with full-dose and low-dose TKI: Results from real-world practice
por: Chen, Yilin, et al.
Publicado: (2023)

Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease
por: Dagenais, Gilles R, et al.
Publicado: (2021)

Development and Validation of a Novel Tool for the Prediction of Clopidogrel Response in Chinese Acute Coronary Syndrome Patients: The GeneFA Score
por: Wu, Hongyi, et al.
Publicado: (2022)

Mechanism and Potential Target of Blood-Activating Chinese Botanical Drugs Combined With Anti-Platelet Drugs: Prevention and Treatment of Atherosclerotic Cardiovascular Diseases
por: Li, Dan, et al.
Publicado: (2022)

Mechanism of Improving Aspirin Resistance: Blood-Activating Herbs Combined With Aspirin in Treating Atherosclerotic Cardiovascular Diseases
por: Zhao, Yixi, et al.
Publicado: (2021)

Case Report: Arterial Wall Inflammation in Atherosclerotic Cardiovascular Disease is Reduced by Olamkicept (sgp130Fc)
por: Schulte, Dominik M., et al.
Publicado: (2022)

Evaluation of Herb–Drug Interaction Between Danshen and Rivaroxaban in Rat and Human Liver Microsomes
por: Wang, Xu, et al.
Publicado: (2022)

Vascular Adhesion Protein-1 (VAP-1)/Semicarbazide-Sensitive Amine Oxidase (SSAO): A Potential Therapeutic Target for Atherosclerotic Cardiovascular Diseases
por: Li, Hui, et al.
Publicado: (2021)

Rivaroxaban Modulates TLR4/Myd88/NF-Kβ Signaling Pathway in a Dose-Dependent Manner With Suppression of Oxidative Stress and Inflammation in an Experimental Model of Depression
por: Abdelzaher, Walaa Yehia, et al.
Publicado: (2021)

Corrigendum: Evaluation of herb–drug interaction between Danshen and rivaroxaban in rat and human liver microsomes
por: Wang, Xu, et al.
Publicado: (2022)

Prediction of Rivaroxaban-Rifampin Interaction After Major Orthopedic Surgery: Physiologically Based Pharmacokinetic Modeling and Simulation
por: Xu, Rui-juan, et al.
Publicado: (2021)

Influence of ABCB1 Gene Polymorphism on Rivaroxaban Blood Concentration and Hemorrhagic Events in Patients With Atrial Fibrillation
por: Wang, Yan, et al.
Publicado: (2021)

Circular RNA hsa_circ_0003574 as a biomarker for prediction and diagnosis of ischemic stroke caused by intracranial atherosclerotic stenosis
por: Li, Lingfei, et al.
Publicado: (2022)

Mechanistic Insight into PPARγ and Tregs in Atherosclerotic Immune Inflammation
por: Gao, Zhao, et al.
Publicado: (2021)

Adipose-derived stem cell/FGF19-loaded microfluidic hydrogel microspheres for synergistic restoration of critical ischemic limb()
por: Wang, Ruihan, et al.
Publicado: (2023)

Quantitative Systems Pharmacology Model-Based Predictions of Clinical Endpoints to Optimize Warfarin and Rivaroxaban Anti-Thrombosis Therapy
por: Hartmann, Sonja, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_s8ddhdv6nrd7vbo6thhjft35pc